DrugPatentWatch Database Preview
Patent: 10,071,170
» See Plans and Pricing
Summary for Patent: 10,071,170
| Title: | Antibody-drug conjugate having improved stability and use thereof |
| Abstract: | The present invention relates to an antibody-drug conjugate comprising a drug conjugated to an antibody, a preparation method thereof and the use thereof. |
| Inventor(s): | Kim; Young Min (Gyeonggi-do, KR), Ko; Min Ji (Daejeon, KR), Kim; Jae Yong (Seoul, KR), Kim; Ju Hee (Daejeon, KR), Moon; Kyung Duk (Daejeon, KR), Song; Dae Hae (Daejeon, KR), Eom; Jae Hyun (Sejong, KR), Jung; Jin Won (Dajeon, KR) |
| Assignee: | ABLBIO (Seoul, KR) |
| Application Number: | 14/898,126 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,071,170
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | Start Trial | ABLBIO (Seoul, KR) | 2033-06-24 | RX | search | |
| Genentech | HERCEPTIN | trastuzumab | VIAL; INTRAVENOUS | 103792 | 001 | 1998-09-25 | Start Trial | ABLBIO (Seoul, KR) | 2033-06-24 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 10,071,170
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2014208987 | Start Trial |
| United States of America | 2016136300 | Start Trial |
| United States of America | 2018360986 | Start Trial |
| Russian Federation | 2016102116 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
